IBRX Q2 2017 Earnings — ImmunityBio, Inc. Revenue & Financial Results | Market Cap Arena

IBRXImmunityBio, Inc.

$8B

Q2 2017 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$14,000+16.7% YoY

Gross Profit

$14,000100.0% margin

Operating Income

-$23M-167300.0% margin

Net Income

-$23M-167514.3% margin

EPS (Diluted)

$-0.07

QoQ Revenue Growth

+27.3%

Cash Flow

Operating Cash Flow

-$15M

Free Cash Flow

-$23M

Stock-Based Comp.

$9M

Balance Sheet

Total Assets

$302M

Total Liabilities

$49M

Stockholders' Equity

$253M

Cash & Equivalents

$39M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$14,000	$12,000	+16.7%
Gross Profit	$14,000	$12,000	+16.7%
Operating Income	-$23M	-$34M	+31.6%
Net Income	-$23M	-$34M	+31.0%

Geographic Segments

San Diego California

$15,000100%